Drug Trial Radar · NCT06745583
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Dec 16, 2024
Primary completion
Mar 6, 2026
Study completion May 6, 2026
Sponsor
- Lead sponsor
- Elixiron Immunotherapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
Conditions
- Mild, Moderate, or Severe Alzheimer's Disease
Interventions
EI-1071 tablet, oralDrug
Dose: 448.2 mg BID for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the change of neuroinflammation in brains of AD patients after dosing with EI-1071 by PETTime frame: Baseline, Day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Taipei Veterans General Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.